Markqayne Ray
ORCID：0000-0001-8691-3756
发表论文 40 篇 · 总被引 255 次 · h-index 7
代表论文
- A Cost-Effectiveness Analysis of Axicabtagene Ciloleucel versus Tisagenlecleucel in the Treatment of Diffuse Large B-cell Lymphoma Based on a Real-World French Registry (2024 · Advances in Therapy · 被引 6)
- Axi-cel delivers similar outcomes regardless of ASCT-eligibility in second line R/R LBCL: Combined data from ZUMA-7 and ALYCANTE (2025 · Blood · 被引 2)
- Patient and physician treatment preferences in relapsed/refractory follicular lymphoma: a discrete choice experiment in the United States, United Kingdom, France, Germany, Brazil, and Japan (2025 · Frontiers in Oncology · 被引 2)
- Short-Term Costs Associated with Outpatient Use of Axicabtagene Ciloleucel in Second-Line Relapsed/Refractory Large B-Cell Lymphoma Based on Zuma-24 Clinical Trial (2025 · Transplantation and Cellular Therapy · 被引 2)
- A Cost-Effectiveness Analysis of Diffuse Large B-Cell Lymphoma Treatment Pathways in the United States (2025 · MDM Policy & Practice · 被引 1)
- A United States (US) Cost-Effectiveness Analysis of Axicabtagene Ciloleucel Compared to Odronextamab in Third Line or Later (3L+) Diffuse Large B-Cell Lymphoma (2024 · Blood · 被引 1)